Payment overview · 2025
General Payments
$975.74
46 reported records · 15 companies
Healthcare provider profile · identity verified
Aaron Maurice Locklear, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PEMBROKE, NC · NPI 1265852685
Verified facts
What the public records show
CMS Open Payments records show Aaron Maurice Locklear, M.D. received $975.74 in general payments during 2025 across 46 reported records.
Novo Nordisk Inc accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Vraylar, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $196.39 | 20.1% | 11 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $189.35 | 19.4% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $144.10 | 14.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $108.58 | 11.1% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $80.04 | 8.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.21 | 4.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.30 | 4.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $32.36 | 3.3% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $31.21 | 3.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.45 | 2.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.96 | 1.9% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.59 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.50 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.49 | 1.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.21 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $975.74 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $189.35 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $144.10 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $120.47 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $110.11 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $80.04 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $75.92 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $59.32 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $49.26 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.21 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.21 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $39.30 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $32.36 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $31.21 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 100 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 53 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
100 | 38 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 859 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 440 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 283 | 74 |
| Lisinopril | Lisinopril | 278 | 76 |
| Omeprazole | Omeprazole | 236 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 228 | 52 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 227 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 205 | 25 |
| Furosemide | Furosemide | 186 | 50 |
| Montelukast Sodium | Montelukast Sodium | 172 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 164 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 157 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 149 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 39 |
| Trazodone Hcl | Trazodone Hcl | 135 | 30 |
| Celecoxib | Celecoxib | 134 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 32 |
| Carvedilol | Carvedilol | 124 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 120 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 110 | 11 |
| Prednisone | Prednisone | 109 | 79 |
| Allopurinol | Allopurinol | 104 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 29 |
| Potassium Chloride | Potassium Chloride | 101 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 29 |
| Linzess | Linaclotide | 100 | 38 |
| Alprazolam | Alprazolam | 98 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 19 |
| Losartan Potassium | Losartan Potassium | 96 | 24 |
| Metformin Hcl | Metformin Hcl | 90 | 23 |
| Ozempic | Semaglutide | 89 | 23 |
| Tramadol Hcl | Tramadol Hcl | 87 | 21 |
| Simvastatin | Simvastatin | 84 | 17 |
| Meloxicam | Meloxicam | 82 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 19 |
| Pregabalin | Pregabalin | 75 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 69 | 54 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 67 | 14 |
| Methocarbamol | Methocarbamol | 66 | 17 |
| Buspirone Hcl | Buspirone Hcl | 65 | 17 |
| Glipizide Er | Glipizide | 59 | 16 |
| Ondansetron Odt | Ondansetron | 58 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 49 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 14 |
| Colchicine | Colchicine | 56 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 14 |
| Mounjaro | Tirzepatide | 53 | 11 |
| Sertraline Hcl | Sertraline Hcl | 52 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Eliquis | Apixaban | 49 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 48 | 12 |
| Jardiance | Empagliflozin | 47 | 16 |
| Metformin Hcl Er | Metformin Hcl | 47 | 16 |
| Baclofen | Baclofen | 46 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | 12 |
| Famotidine | Famotidine | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 16 |
| Mirtazapine | Mirtazapine | 42 | 13 |
| Promethazine Hcl | Promethazine Hcl | 42 | 12 |
| Atenolol | Atenolol | 41 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 15 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 20 |
| Glipizide | Glipizide | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 36 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 35 | 16 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 12 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 12 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 12 |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Azithromycin | Azithromycin | 14 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $975.74 · 46 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, CREON, Heplisav-B, IBSRELA, JARDIANCE, Korlym, LINZESS, MOUNJARO, Ozempic, PURAPLY WOUND MATRIX, REXULTI, Rybelsus, TZIELD, The Cologuard Plus Collection Kit, VIBERZI, VOQUEZNA, VRAYLAR, WaveWriter Alpha Prime 16, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error